BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
See today's BioWorld
Home
» F2G pads coffers with $70M as novel antifungal approaches finish line
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
F2G pads coffers with $70M as novel antifungal approaches finish line
Aug. 4, 2022
By
Nuala Moran
No Comments
F2G Ltd. has raised a further $70 million in venture capital as it continues preparations to submit a new drug application to the U.S. FDA for its novel antifungal drug, olorofim, before the end of 2022.
BioWorld
Financings
Infection